6 research outputs found
Digoxin Inhibits Retinoblastoma through Suppressing a Non-canonical TGFβ Signaling Pathway.
Aims: Retinoblastoma is a childhood ocular tumor rapidly developing from the immature cells of
the retina due to loss of functional retinoblastoma protein. Digoxin, a cardiac glycoside, has been
reported to be effective in inducing apoptosis, cell cycle arrest, and cytotoxic effects on human
cancers. In this regard, the present study aims to investigate whether digoxin could suppress
retinoblastoma cancer through the regulation of transforming growth factor-β (TGF-β) signaling
pathway.
Methodology: The effects of digoxin on Y-79 cells, retinoblastoma cancer cell line, were
investigated using MTT (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazoli-umbromide) and BrdU
(bromodeoxyuridine) assays to measure cellular cytotoxicity effects and cell apoptosis,
respectively. Also, a qPCR assay was employed to analyze the mRNA expression levels of TGFβ
signaling pathway including C-MYC, P21, P15, TGFβRI, TGFβRII, and SMAD2, 3, and 4 genes.
Results: The results of the cell function assays revealed that digoxin inhibited the cell viability and
proliferation of Y-79 cells. In addition, it was found that digoxin significantly suppressed C-MYC
expression and enhanced the expression of P21, P15, SMAD2 and SMAD4 genes in a dose-and
time-dependent manner. However, the obtained results could not detect any significant effect of
digoxin on TGFβRI, TGFβRII and SMAD3 genes.
Conclusion: Taken together, the findings of the present study suggest that digoxin could be a
potential therapeutic agent in the treatment of retinoblastoma by regulating the cell cycle genes via
a non-canonical TGF-β signaling pathway
Transforming Growth Factor Beta-Induced Factor 2-Linked X (TGIF2LX) Regulates Two Morphogenesis Genes, Nir1 and Nir2 in Human Colorectal
Abstract- A member of homeodomain protein namely TGIF2LX has been implicated as a tumor suppressor
gene in human malignancy as well as in spermatogenesis. However, to our knowledge, dynamic functional
evidence of the TGIF2LX has not yet been provided. The aim of the present study was to investigate the
human TGIF2LX target gene(s) using a cDNA-AFLP as a differential display method. A pEGFP-TGIF2LX
construct containing the wild-type TGIF2LX cDNA was stably transfected into SW48 cells. UV microscopic
analysis and Real-time RT-PCR were used to confirm TGIF2LX expression. The mRNA expressions of
TGIF2LX in transfected SW48 cells, the cells containing empty vector (pEGFP-N), and untransfected cells
were compared. Also, a Real-time PCR technique was applied to validate cDNA-AFLP results. The results
revealed a significant down-regulation and up-regulationby TGIF2LX of Nir1 and Nir2 genes, respectively.
The genes are engaged in the cell morphogenesis process. Our findings may provide new insight into the
complex molecular pathways underlying colorectal cancer development
Decreased serum levels of angiotensin converting enzyme (ACE)2 and enhanced cytokine levels with severity of COVID-19: normalisation upon disease recovery
Background:SARS-CoV-2 causes coronavirus disease 2019 (COVID-19). Circulating soluble angiotensin-converting enzyme (sACE2), the main receptor for SARS-CoV-2, together with components of the renin-angiotensin system promote infection and disease severity. Objective: In this pilot study we followed the time-course of sACE2 levels in relation to systemic cytokines in severe and moderate COVID-19 patients treated with remdesivir/dexamethasone in combination. Methods: Peripheral blood was obtained upon admission from 30 patients (12 with moderate disease and 18 with severe disease) and 14 patients with PCR-confirmed mild COVID-19. Severe and moderate patients were treated with remdesivir (200mg/first day and 100mg/day for the remaining days ) and dexamethasone (100mg/day ). 6 healthy control subjects (HC) were also enrolled. Serum interleukin (IL)-6 and IL-8 and sACE2 levels were measured by ELISA at baseline and during treatment in severe and moderate patients and at baseline in mild and HCs. Results: Baseline sACE2 levels were lower in severe (p=0.0005) and moderate (p=0.0022) patients than in patients with mild COVID-19 and in HC (p=0.0023 and p=0.0012 respectively). Serum sACE2 levels increased in patients with severe disease recovered over time compared with moderate (p=0.0021) and severe (p=0.0411) COVID-19 subjects at baseline. Systemic IL-6 and IL-8 levels were higher in all patient groups compared with HC and were not significantly affected over time or by remdesivir/dexamethasone treatment for 5 days. Conclusion: Serum sACE2 levels increase in severe COVID-19 patients as they recover over time whilst circulating cytokines are unaffected. Future studies should link these results to clinical outcomes. Funding: IMA is financially supported by the Welcome Trust (093080/Z/10/Z), the EPSRC (EP/T003189/1), and the Community Jameel Imperial College COVID-19 Excellence Fund (G26290) and by the UK MRC (MR/T010371/1). SM is supported by EU project 853850. Declaration of Interests: The authors declare that there is no conflict of interest to this article. Ethics Approval Statement: The study was approved by the institutional ethics board of the Masih Daneshvari Hospital (Ethics number SBMU.NRITLD.REC.1399.226)
Effect of atorvastatin on orthodontic tooth movement in male wistar rats.
Statins are used as cholesterol-lowering drugs by many patients and have been recently shown to affect bone metabolism. The aim of this study was to determine the effect of atorvastatinon on orthodontic tooth movement (OTM) in rats.Thirty-six adult male Sprague-Dawley rats were randomly divided into three groups of 12 samples each. Group A, served as control with no medication while groups B and C received a daily gavage of carboxymethyl cellulose (CMC) as vehicle and atorvastatin (5 mg/kg) as test substance, respectively. In all three groups, 6mm nickel-titanium closed-coil springs were ligated between the maxillary incisors and first left molars to deliver an initial force of 60g. Tooth movement was measured following sacrifice, 21 days after appliance insertion. Root resorption, PDL width and osteoclast number were histologically evaluated and compared between the groups.The mean amount of tooth movement was 0.62 mm in group A, 0.59 mm in group B and 0.38 mm in group C. OTM reduction following administration of atorvastatin was statistically significant (p0.05).According to the results obtained in the current study, atorvastatin appears to reduce tooth movement in rats; however its effect on osteoclasts, especially osteoclastic function, requires further investigation
Decreased serum levels of angiotensin converting enzyme (ACE)2 and enhanced cytokine levels with severity of COVID-19: normalisation upon disease recovery
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). Circulating soluble angiotensin-converting enzyme (sACE2)2, the main receptor for SARS-CoV-2, together with components of the renin-angiotensin system promote infection and disease severity. Objective: This pilot study followed the time-course of sACE2 levels in relation to systemic cytokines in severe and moderate COVID-19 patients treated with remdesivir/dexamethasone in combination. Methods: Peripheral blood was obtained upon admission from 30 patients (12 with moderate disease and 18 with severe disease) and 14 patients with PCR-confirmed mild COVID-19. Severe and moderate patients were treated with remdesivir (200mg/first day and 100mg/day for the remaining days) and dexamethasone (100mg/day). 6 healthy control subjects (HC) were also enrolled. Serum interleukin (IL)-6 and IL-8 and sACE2 levels were measured by ELISA at baseline and during treatment in severe and moderate patients and at baseline in mild and HCs. Results: Baseline sACE2 levels were lower in severe (p = 0.0005) and moderate (p = 0.0022) patients than in patients with mild COVID-19 and in HC (p = 0.0023 and p = 0.0012 respectively). Treatment significantly increased sACE2 levels in patients with moderate disease (p = 0.0156) but only 50% of patients with severe disease showed enhanced levels compared to baseline. Systemic IL-6 and IL-8 levels were higher in all patient groups compared with HC and were not significantly affected over time or by remdesivir/dexamethasone treatment for 5 days. Conclusion: Serum sACE2 levels increase in severe COVID-19 patients as they recover over time whilst circulating cytokines are unaffected. Future studies should link these results to clinical outcomes
Decreased serum levels of angiotensin converting enzyme (ACE)2 and enhanced cytokine levels with severity of COVID-19: normalisation upon disease recovery
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). Circulating soluble angiotensin-converting enzyme (sACE2)2, the main receptor for SARS-CoV-2, together with components of the renin-angiotensin system promote infection and disease severity. Objective: This pilot study followed the time-course of sACE2 levels in relation to systemic cytokines in severe and moderate COVID-19 patients treated with remdesivir/dexamethasone in combination. Methods: Peripheral blood was obtained upon admission from 30 patients (12 with moderate disease and 18 with severe disease) and 14 patients with PCR-confirmed mild COVID-19. Severe and moderate patients were treated with remdesivir (200mg/first day and 100mg/day for the remaining days) and dexamethasone (100mg/day). 6 healthy control subjects (HC) were also enrolled. Serum interleukin (IL)-6 and IL-8 and sACE2 levels were measured by ELISA at baseline and during treatment in severe and moderate patients and at baseline in mild and HCs. Results: Baseline sACE2 levels were lower in severe (p = 0.0005) and moderate (p = 0.0022) patients than in patients with mild COVID-19 and in HC (p = 0.0023 and p = 0.0012 respectively). Treatment significantly increased sACE2 levels in patients with moderate disease (p = 0.0156) but only 50% of patients with severe disease showed enhanced levels compared to baseline. Systemic IL-6 and IL-8 levels were higher in all patient groups compared with HC and were not significantly affected over time or by remdesivir/dexamethasone treatment for 5 days. Conclusion: Serum sACE2 levels increase in severe COVID-19 patients as they recover over time whilst circulating cytokines are unaffected. Future studies should link these results to clinical outcomes